Senti Bio procures $105m Series B

Senti Bio, a gene circuit company, has secured $105 million in Series B financing.

Senti Bio, a gene circuit company, has secured $105 million in Series B financing. Leaps by Bayer, the impact investment arm of Bayer AG, led the round with participation from other investors that included Matrix Partners China, Mirae Asset Capital, Ridgeback Capital and Intel Capital.

Source: Press Release